(Q46679563)

English

Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

1 reference

based on heuristic

inferred from title

author name string

Kazuya Makita

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Ken Ishitani

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Hiroaki Ohta

3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Fumi Horiguchi

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Shiro Nozawa

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Journal of Bone and Mineral Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

23

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

389-394

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

Impact of medical treatment of endometriosis on bone mass

1 reference

https://api.crossref.org/works/10.1007%2FS00774-005-0618-3

21 January 2018

Gonadotropin releasing hormone agonist therapy and its effect on bone mass

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New therapy for endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LHRH analogues and bone loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence that the loss of bone mass induced by GnRH agonists is not totally recovered

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased bone turnover during gonadotropin-releasing hormone superagonist-induced ovulation inhibition.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leuprolide acetate and bone mineral density measured by quantitative digitized radiography

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone mass in endometriosis patients treated with GnRH agonist implant or danazol

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nafarelin therapy in endometriosis: long-term effects on bone mineral density

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term gonadotrophin-releasing hormone agonist therapy: the evolving issue of steroidal 'add-back' paradigms

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interval bone mineral density with long-term gonadotropin-releasing hormone agonist suppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/16133689

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00774-005-0618-3

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/16133689

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46679563&oldid=2208017222"